Rabies vaccine - Beijing Minhai Biotechnology

Drug Profile

Rabies vaccine - Beijing Minhai Biotechnology

Alternative Names: Freeze dried rabies vaccine (MRC-5-cell) - Beijing Minhai Biotechnology; Freeze dried rabies vaccine - Beijing Minhai Biotechnology; HDCV rabies vaccine - Beijing Minhai Biotechnology; Human diploid cell rabies vaccine - Beijing Minhai Biotechnology; MRC-5 cell rabies vaccine - Beijing Minhai Biotechnology

Latest Information Update: 08 Feb 2016

Price : $50

At a glance

  • Originator Beijing Minhai Biotechnology
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rabies

Most Recent Events

  • 15 Oct 2014 The Beijing Center for Disease Control and Prevention plans a phase III trial for Rabies (Prevention, In volunteers, In adolescents, In adults) in China (Parenteral) (NCT02288286)
  • 15 Oct 2014 Beijing Center for Disease Control and Prevention in collaboration with Beijing Minhai Biotechnology plans a phase I trial for Rabies (Prevention, In adolescents, In adults, In volunteers) in China (Parenteral) (NCT02281396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top